BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Molecular Vision Ltd. Strengthens Board, Appoints Dr Chris Hand as Non-Executive Director


4/13/2010 4:19:32 PM

London, UK, 13 April 2010: Molecular Vision, a developer of quantitative point-of-care (POC) diagnostic devices, has announced the appointment of Dr Chris Hand as a Non-Executive Director with immediate effect. The appointment serves to strengthen the Board as the Company moves towards commercialisation of its novel detection technology, which focuses on low cost diagnostic tests in a miniaturised, easy-to-use, disposable format.

Dr Hand has over 20 years’ experience in the medical diagnostics market. He was CEO of medical diagnostics company Cozart plc until its acquisition by Concateno plc in October 2007. Dr Hand co-founded Cozart with £30,000 in 1993, led a successful VC fundraising in 2001 and AIM flotation in 2004 before the £65m sale of the business in late 2007. He remained a non-executive director of Concateno until its acquisition by Inverness Medical Innovations in 2009. Dr Hand has a DPhil in biochemistry from Oxford University.

“It is indicative of the strength of the company that we have attracted someone of Dr Hand’s standing,” said Dr Ian Campbell, CEO, Molecular Vision: “His considerable experience in carrying a diagnostic company through from start-up to sale, and extensive industry knowledge, will prove invaluable as we grow Molecular Vision.”

Dr Hand commented: “I am delighted to join Molecular Vision’s Board and look forward to working with the team as the company enters the next phase of its growth."

About Molecular Vision Limited

Molecular Vision is developing low-cost, easy-to-use microfluidic devices for medical testing that will greatly extend the range of in-house tools available to the general practitioner. The devices are being developed to allow near-patient quantitative diagnosis, currently focusing on key areas of high disease burden such as kidney function and cardiovascular disease. The technology has additional potential applications outside the diagnostics market, including forensic science, homeland security and environmental monitoring.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->